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Introduction 
• Immunosuppressors: drugs used in transplanted patients 
to avoid graft rejection. 
• Therapeutic drug monitoring (TDM) of immunosuppressors 
is important due to its narrow therapeutic window. 
•  Methods used for TDM should have adequate analytical 
performance and turn-around times. 
 
Introduction 
•  Analytical methods available for quantification include 
immunoassay and chromatographic methods (HPLC-UV; 
LC-MS/MS). 
• Liquid chromatography tandem-mass spectrometry (LC-
MS/MS) provide accuracy, speed and sensitivity 
compared to immunoassay based techniques.  
• LC-MS/MS methods have the ability of measure the 
active compound and not drug metabolites.  
Purpose 
• Implementation of a rapid and simple  LC-MS/MS method for 
simultaneous analysis of 4 immunosuppressors in whole blood: 
Cyclosporine A 
(CsA)  
Mw 1202.8 
Everolimus 
(Ever)  
Mw 958.2 
Sirolimus 
(Sir)  
Mw:914.2 
 
Tacrolimus 
(Tac)  
Mw:804.0 
 • Equipment: LC-MS/MS API 3200, AB SCIEX, coupled to  
   HPLC Agilent 1200. 
• Controls and calibrators: available from RECIPE or 
Chromsystems. 
• Method: iMethod from AB SCIEX for simultaneous analysis of 
cyclosporine A, everolimus, tacrolimus and sirolimus. 
Material and Methods 
Material and Methods 
Analyte Q1 (m/z) Q3 (m/z) RT (min.) 
Cyclosporine A 1202.8 425.4 1.17 
Everolimus 975.7 908.7 1.09 
Tacrolimus 821.5 768.4 1.09 
Sirolimus 931.7 864.6 1.09 
Internal standards 
Cyclosporine D 1216.8 425.4 1.17 
Ascomicin 809.5 756.4 1.09 
MS conditions: ESI positive; MRM mode  
MRM transitions for analytes and internal standards  
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HPLC analytical conditions 
Mode Gradient 
Mobile phase A  
water: ammonium acetate: formic 
acid (997:2:1) 
Mobile phase B  
metanol: ammonium acetate: formic 
acid (997:2:1) 
Flow rate 0.750 mL/min 
Column oven temperature 60°C 
Autosampler temperature 10°C 
Pre-column C18; 4x3 mm 
Injection volume 50 µL 
Run time 2 min. 
Material and Methods 
Sample 
preparation  
12000 rpm / 10 min 
200 µL of  
protein precipitation protein 
Add 100 µL of whole blood 
Inject supernatant 
Results and discussion 
Ascomicin (IS) 
Cyclosporine D (IS) 
Cyclosporine A 
(48 ng/ml) 
Tacrolimus 
(2,5 ng/ml) 
Sirolimus 
(2,7 ng/ml) 
Everolimus 
(2,6 ng/ml) 
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Calibration curve 
Analyte 
Range 
(ng/mL) 
R2 
CVm(%) 
<10% 
RIKILT 
Test  
(90-110)% 
Mandel Test 
(PG<F) 
PG F 
Cyclosporine A 48 - 1350  0.9999 1.4 96-102 0.7 18.5 
Everolimus 2.6 – 44.9  0.9997 1.9 89-104 1.5 18.5 
Tacrolimus 2.5 – 39.7 0.9998 2.1 98-102 1.3 18.5 
Sirolimus 2.7 – 44.3 0.9996 2.5 96-107 -2.0 18.5 
1. Linearity 
F: Fisher Snedecor distribution; (1, N-3);95% 
 
Results and discussion 
Analyte LOD (ng/mL) LOQ (ng/mL) 
Cyclosporine A 14 48 
Everolimus 0.9 2.6 
Tacrolimus 0.7 2.5 
Sirolimus 1.0 2.7 
2. Analytical limits 
Results and discussion 
3. Repeatability 
Analyte 
RSD(%) 
Low 
(QC I) 
Medium 
(QC II) 
High 
(QC III) 
Cyclosporine A 3.8 2.7 1.9 
Everolimus 11.2 10.8 8.8 
Tacrolimus 7.9 5.4 5.4 
Sirolimus 12.8 5.3 4.8 
Results and discussion 
4. Accuracy 
Results from participation in UK NEQAS proficiency test 
 Cyclosporine A  
Results and discussion 
4. Accuracy 
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 Everolimus  
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4. Accuracy 
Results from participation in UK NEQAS proficiency test 
 Tacrolimus  
Results and discussion 
4. Accuracy 
Results from participation in UK NEQAS proficiency test 
 Sirolimus 
Results and discussion 
5. Samples 
Results for everolimus blood levels in 35 samples 
Everolimus (ng/mL) 
Subtherapeutic 
range 
(<3) 
Therapeutic 
range 
(3-8) 
Toxic  
range 
(>8) 
Nº of 
samples 
22 (60%) 13 (37%) 1 (2.8 %) 
Conclusions 
• The LC-MS/MS method is linear for all target compounds within the 
range used. The limits of quantification are adequate for TDM of 
CsA, Tac, Ever and Sir. The relative standard deviation for 
repeatability is below 15% for all drugs and the method is 
accurate. 
• Sample preparation is rapid and simple and run time is short which 
enables high throughput. 
• The reported method provides a rapid, specific and accurate 
measurement of CsA, Ever, Sir and Tac over a wide analytical 
range making it suitable for routine use in therapeutic drug 
monitoring. 
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